The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Microbiome Therapeutics Market Research Report 2025
Synopsis
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The global Microbiome Therapeutics market was valued at US$ 91 million in 2023 and is anticipated to reach US$ 892.2 million by 2030, witnessing a CAGR of 38.1% during the forecast period 2024-2030.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
Report Scope
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Segment by Type
Upper GIT
Lower GIT
Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The global Microbiome Therapeutics market was valued at US$ 91 million in 2023 and is anticipated to reach US$ 892.2 million by 2030, witnessing a CAGR of 38.1% during the forecast period 2024-2030.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
Report Scope
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Segment by Type
Upper GIT
Lower GIT
Segment by Application
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Microbiome Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Market by Application
1.3.1 Global Microbiome Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Therapeutics Market Perspective (2019-2030)
2.2 Microbiome Therapeutics Growth Trends by Region
2.2.1 Global Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Microbiome Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Microbiome Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Microbiome Therapeutics Market Dynamics
2.3.1 Microbiome Therapeutics Industry Trends
2.3.2 Microbiome Therapeutics Market Drivers
2.3.3 Microbiome Therapeutics Market Challenges
2.3.4 Microbiome Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Microbiome Therapeutics Players by Revenue
3.1.1 Global Top Microbiome Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Microbiome Therapeutics Revenue
3.4 Global Microbiome Therapeutics Market Concentration Ratio
3.4.1 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Microbiome Therapeutics Revenue in 2023
3.5 Microbiome Therapeutics Key Players Head office and Area Served
3.6 Key Players Microbiome Therapeutics Product Solution and Service
3.7 Date of Enter into Microbiome Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Microbiome Therapeutics Breakdown Data by Type
4.1 Global Microbiome Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2025-2030)
5 Microbiome Therapeutics Breakdown Data by Application
5.1 Global Microbiome Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Microbiome Therapeutics Market Size (2019-2030)
6.2 North America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Microbiome Therapeutics Market Size by Country (2019-2024)
6.4 North America Microbiome Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Microbiome Therapeutics Market Size (2019-2030)
7.2 Europe Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Microbiome Therapeutics Market Size by Country (2019-2024)
7.4 Europe Microbiome Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Microbiome Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Microbiome Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Microbiome Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Microbiome Therapeutics Market Size (2019-2030)
9.2 Latin America Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Microbiome Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Microbiome Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Microbiome Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Microbiome Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Microbiome Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Detail
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Therapeutics Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2019-2024)
11.1.5 Seres Therapeutics Recent Development
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Detail
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Therapeutics Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2019-2024)
11.2.5 Assembly Biosciences Recent Development
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Detail
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Therapeutics Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2019-2024)
11.3.5 Synthetic Biologics Recent Development
11.4 Interxon
11.4.1 Interxon Company Detail
11.4.2 Interxon Business Overview
11.4.3 Interxon Microbiome Therapeutics Introduction
11.4.4 Interxon Revenue in Microbiome Therapeutics Business (2019-2024)
11.4.5 Interxon Recent Development
11.5 PureTech
11.5.1 PureTech Company Detail
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Therapeutics Introduction
11.5.4 PureTech Revenue in Microbiome Therapeutics Business (2019-2024)
11.5.5 PureTech Recent Development
11.6 Synlogic
11.6.1 Synlogic Company Detail
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Therapeutics Introduction
11.6.4 Synlogic Revenue in Microbiome Therapeutics Business (2019-2024)
11.6.5 Synlogic Recent Development
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Detail
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Therapeutics Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Therapeutics Business (2019-2024)
11.7.5 Enterome BioScience Recent Development
11.8 4D Pharma
11.8.1 4D Pharma Company Detail
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Therapeutics Introduction
11.8.4 4D Pharma Revenue in Microbiome Therapeutics Business (2019-2024)
11.8.5 4D Pharma Recent Development
11.9 Second Genome
11.9.1 Second Genome Company Detail
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Therapeutics Introduction
11.9.4 Second Genome Revenue in Microbiome Therapeutics Business (2019-2024)
11.9.5 Second Genome Recent Development
11.10 AOBiome
11.10.1 AOBiome Company Detail
11.10.2 AOBiome Business Overview
11.10.3 AOBiome Microbiome Therapeutics Introduction
11.10.4 AOBiome Revenue in Microbiome Therapeutics Business (2019-2024)
11.10.5 AOBiome Recent Development
11.11 C3 Jian
11.11.1 C3 Jian Company Detail
11.11.2 C3 Jian Business Overview
11.11.3 C3 Jian Microbiome Therapeutics Introduction
11.11.4 C3 Jian Revenue in Microbiome Therapeutics Business (2019-2024)
11.11.5 C3 Jian Recent Development
11.12 Rebiotix
11.12.1 Rebiotix Company Detail
11.12.2 Rebiotix Business Overview
11.12.3 Rebiotix Microbiome Therapeutics Introduction
11.12.4 Rebiotix Revenue in Microbiome Therapeutics Business (2019-2024)
11.12.5 Rebiotix Recent Development
11.13 MicroBiome Therapeutics LLC
11.13.1 MicroBiome Therapeutics LLC Company Detail
11.13.2 MicroBiome Therapeutics LLC Business Overview
11.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Introduction
11.13.4 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2019-2024)
11.13.5 MicroBiome Therapeutics LLC Recent Development
11.14 Metabiomics
11.14.1 Metabiomics Company Detail
11.14.2 Metabiomics Business Overview
11.14.3 Metabiomics Microbiome Therapeutics Introduction
11.14.4 Metabiomics Revenue in Microbiome Therapeutics Business (2019-2024)
11.14.5 Metabiomics Recent Development
11.15 Ritter Pharmaceuticals
11.15.1 Ritter Pharmaceuticals Company Detail
11.15.2 Ritter Pharmaceuticals Business Overview
11.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Introduction
11.15.4 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2019-2024)
11.15.5 Ritter Pharmaceuticals Recent Development
11.16 Symberix
11.16.1 Symberix Company Detail
11.16.2 Symberix Business Overview
11.16.3 Symberix Microbiome Therapeutics Introduction
11.16.4 Symberix Revenue in Microbiome Therapeutics Business (2019-2024)
11.16.5 Symberix Recent Development
11.17 OpenBiome
11.17.1 OpenBiome Company Detail
11.17.2 OpenBiome Business Overview
11.17.3 OpenBiome Microbiome Therapeutics Introduction
11.17.4 OpenBiome Revenue in Microbiome Therapeutics Business (2019-2024)
11.17.5 OpenBiome Recent Development
11.18 Azitra
11.18.1 Azitra Company Detail
11.18.2 Azitra Business Overview
11.18.3 Azitra Microbiome Therapeutics Introduction
11.18.4 Azitra Revenue in Microbiome Therapeutics Business (2019-2024)
11.18.5 Azitra Recent Development
11.19 Symbiotix Biotherapies
11.19.1 Symbiotix Biotherapies Company Detail
11.19.2 Symbiotix Biotherapies Business Overview
11.19.3 Symbiotix Biotherapies Microbiome Therapeutics Introduction
11.19.4 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2019-2024)
11.19.5 Symbiotix Biotherapies Recent Development
11.20 Osel
11.20.1 Osel Company Detail
11.20.2 Osel Business Overview
11.20.3 Osel Microbiome Therapeutics Introduction
11.20.4 Osel Revenue in Microbiome Therapeutics Business (2019-2024)
11.20.5 Osel Recent Development
11.21 Metabogen
11.21.1 Metabogen Company Detail
11.21.2 Metabogen Business Overview
11.21.3 Metabogen Microbiome Therapeutics Introduction
11.21.4 Metabogen Revenue in Microbiome Therapeutics Business (2019-2024)
11.21.5 Metabogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
